Cargando…

P2Y13 Receptor Regulates HDL Metabolism and Atherosclerosis In Vivo

High-density lipoprotein (HDL) is known to protect against atherosclerosis by promoting the reverse cholesterol transport. A new pathway for the regulation of HDL-cholesterol (HDL-c) removal involving F1-ATPase and P2Y13 receptor (P2Y13R) was described in vitro, and recently in mice. However, the ph...

Descripción completa

Detalles Bibliográficos
Autores principales:	Goffinet, Marine, Tardy, Claudine, Boubekeur, Nadia, Cholez, Guy, Bluteau, Alice, Oniciu, Daniela C., Lalwani, Narendra D., Dasseux, Jean-Louis H., Barbaras, Ronald, Baron, Rudi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4000210/ https://www.ncbi.nlm.nih.gov/pubmed/24769858 http://dx.doi.org/10.1371/journal.pone.0095807

Ejemplares similares

HDL and CER-001 Inverse-Dose Dependent Inhibition of Atherosclerotic Plaque Formation in apoE(-/-) Mice: Evidence of ABCA1 Down-Regulation
por: Tardy, Claudine, et al.
Publicado: (2015)

Development of CER-001: Preclinical Dose Selection Through to Phase I Clinical Findings
por: Keyserling, Constance H., et al.
Publicado: (2017)

HDL, Atherosclerosis, and Emerging Therapies
por: Hafiane, Anouar, et al.
Publicado: (2013)

Non-clinical development of CER-001
por: Barbaras, Ronald
Publicado: (2015)

HDL Improves Cholesterol and Glucose Homeostasis and Reduces Atherosclerosis in Diabetes-Associated Atherosclerosis
por: Di Bartolo, Belinda A., et al.
Publicado: (2021)

Levels of Cholesterol in Small LDL Particles Predict Atherosclerosis Progression and Incident CHD in the HDL-Atherosclerosis Treatment Study (HATS)
por: Williams, Paul T., et al.
Publicado: (2013)

Current and Emerging Reconstituted HDL-apoA-I and HDL-apoE Approaches to Treat Atherosclerosis
por: Valanti, Eftaxia-Konstantina, et al.
Publicado: (2018)

HDL signaling and protection against coronary artery atherosclerosis in mice
por: Trigatti, Bernardo L, et al.
Publicado: (2016)

Roles of the Metabolic Syndrome, HDL Cholesterol, and Coronary Atherosclerosis in Subclinical Inflammation
por: Rein, Philipp, et al.
Publicado: (2010)

Dysfunctional HDL and progression of atherosclerosis in HIV-1-infected and -uninfected adults
por: Kelesidis, Theodoros, et al.
Publicado: (2013)

The LDL-HDL Profile Determines the Risk of Atherosclerosis: A Mathematical Model
por: Hao, Wenrui, et al.
Publicado: (2014)

HDL-apoA-I Exchange: Rapid Detection and Association with Atherosclerosis
por: Borja, Mark S., et al.
Publicado: (2013)

Synergetic Effect of rHDL and LXR Agonist on Reduction of Atherosclerosis in Mice
por: Morin, Emily E., et al.
Publicado: (2020)

TG/HDL Ratio: A marker for insulin resistance and atherosclerosis in prediabetics or not?
por: Chauhan, Ajay, et al.
Publicado: (2021)

Triglyceride/HDL-Cholesterol Ratio as an Index of Intracranial Atherosclerosis in Nonstroke Individuals
por: Woo, Min-Hee, et al.
Publicado: (2021)

HDL Size is More Accurate than HDL Cholesterol to Predict Carotid Subclinical Atherosclerosis in Individuals Classified as Low Cardiovascular Risk
por: Parra, Eliane Soler, et al.
Publicado: (2014)

Lack of Correlation of Plasma HDL With Fecal Cholesterol and Plasma Cholesterol Efflux Capacity Suggests Importance of HDL Functionality in Attenuation of Atherosclerosis
por: Srivastava, Neelam, et al.
Publicado: (2018)

Vasculitis, Atherosclerosis, and Altered HDL Composition in Heme-Oxygenase-1-Knockout Mice
por: Ishikawa, Kazunobu, et al.
Publicado: (2012)

Simultaneous Noninvasive Detection and Therapy of Atherosclerosis Using HDL Coated Gold Nanorods
por: Ankri, Rinat, et al.
Publicado: (2022)

Atherosclerosis and atherosensitivity in two southwest Algerian desert rodents, Psammomys obesus and Gerbillus gerbillus, and in Rattus norvegicus
por: El-Aoufi, Salima, et al.
Publicado: (2012)

HDL/ApoA-1 infusion and ApoA-1 gene therapy in atherosclerosis
por: Chyu, Kuang-Yuh, et al.
Publicado: (2015)

HDL Mimetics Infusion and Regression of Atherosclerosis: Is It Still Considered a Valid Therapeutic Option?
por: Karalis, I., et al.
Publicado: (2018)

Therapeutic FGF19 promotes HDL biogenesis and transhepatic cholesterol efflux to prevent atherosclerosis
por: Zhou, Mei, et al.
Publicado: (2019)

Hepatocyte ATF3 protects against atherosclerosis by regulating HDL and bile acid metabolism
por: Xu, Yanyong, et al.
Publicado: (2021)

Peptide-Based HDL as an Effective Delivery System for Lipophilic Drugs to Restrain Atherosclerosis Development
por: Gao, Junwei, et al.
Publicado: (2022)

HDL and chronic kidney disease
por: Pavanello, Chiara, et al.
Publicado: (2023)

Niacin Reduces Atherosclerosis Development in APOE*3Leiden.CETP Mice Mainly by Reducing NonHDL-Cholesterol
por: Kühnast, Susan, et al.
Publicado: (2013)

The Association between HDL-C and Subclinical Atherosclerosis Depends on CETP Plasma Concentration: Insights from the IMPROVE Study
por: Colombo, Gualtiero I., et al.
Publicado: (2021)

Associations between LDL/HDL-cholesterol ratio and thoracic and abdominal aortic atherosclerosis assessed by MRI
por: Momiyama, Yukihiko, et al.
Publicado: (2012)

HDL cholesterol efflux capacity in rheumatoid arthritis patients: contributing factors and relationship with subclinical atherosclerosis
por: Tejera-Segura, Beatriz, et al.
Publicado: (2017)

Effects of particulate matter on atherosclerosis: a link via high-density lipoprotein (HDL) functionality?
por: Holme, Siri A. N., et al.
Publicado: (2020)

Scavenger Receptor BI Induced by HDL From Coronary Heart Disease May Be Related to Atherosclerosis
por: Gao, Fen, et al.
Publicado: (2021)

Very low levels of HDL cholesterol and atherosclerosis, a variable relationship – a review of LCAT deficiency
por: Savel, Julia, et al.
Publicado: (2012)

Lower HDL-C levels are associated with higher expressions of CD16 on monocyte subsets in coronary atherosclerosis
por: Xiang, Yang, et al.
Publicado: (2020)

Association of Prolonged Disease Duration and TG/HDL-C Ratio in Accelerating Atherosclerosis in Patients with Takayasu's Arteritis
por: Du, Juan, et al.
Publicado: (2022)

The Current Status of Research on High-Density Lipoproteins (HDL): A Paradigm Shift from HDL Quantity to HDL Quality and HDL Functionality
por: Cho, Kyung-Hyun
Publicado: (2022)

Alterations of HDL’s to piHDL’s Proteome in Patients with Chronic Inflammatory Diseases, and HDL-Targeted Therapies
por: Vyletelová, Veronika, et al.
Publicado: (2022)

Anacetrapib reduces progression of atherosclerosis, mainly by reducing non-HDL-cholesterol, improves lesion stability and adds to the beneficial effects of atorvastatin
por: Kühnast, Susan, et al.
Publicado: (2015)

HDL Cholesterol Story Is Dead: Long Live HDL!
por: Simha, Vinaya, et al.
Publicado: (2016)

Air Pollution: Another Threat to HDL Function
por: Ossoli, Alice, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_sj94djtsr79ovmee10dtnt1mer